| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04059198 Details | 2020-07-21 Interventional | 2 | 5 | Tenofovir Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch… HBV | Evidence of liver injury in a separate Inarigavir study - | |||
| NCT04066647 Details | 2020-07-17 Interventional | 1/2 | 7 | Dexamethasone Dexamethasone E… | Interim analysis shows results opposite of hypothesized. - | |||
| NCT03026166 2016-003686-26 Details | 2020-07-17 Interventional | 1/2 | 42 | Ipilimumab Nivolumab Rovalpituzumab … Lung Neoplasms Small Cell Lung… Small Cell Lung… | Enrollment was stopped after the dose-limiting toxicity (DLT) evaluation phase of Cohort 2. - | |||
| NCT02819544 Details | 2020-07-17 Interventional | 3 | 0 | Ropivacaine Pain Surgery | investigator choice - | |||
| NCT01982864 Details | 2020-07-17 Interventional | 4 | [1 Refs] | 24 | Gentamicins Kidney Failure,… Renal Failure C… | Not enough patients - | ||
| NCT04406610 Details | 2020-07-16 Interventional | 1/2 | 0 | Immunomodulatin… Glioma CAR-T Cell Immu… Glioma of Brain | Project terminated due to revision of local regulations - | |||
| NCT04088032 Details | 2020-07-16 Interventional | 1 | 0 | Aromatase Inhib… Durvalumab Breast Neoplasm… Neoplasms Breast Cancer F… Hormone Recepto… Locally Advance… | Per sponsor - | |||
| NCT03252171 Details | 2020-07-16 Interventional | 1/2 | 0 | Immunomodulatin… Glioma CAR-T Cell Immu… GD2 Positive Gl… | Project terminated due to revision of local regulations - | |||
| NCT02723942 Details | 2020-07-16 Interventional | 1/2 | 0 | Immunomodulatin… Carcinoma Carcinoma, Hepa… CAR-T Cell Immu… GPC3 Positive H… | Project terminated due to revision of local regulations - | |||
| NCT02032784 Details | 2020-07-16 Interventional | 4 | 33 | Octreotide Adenoma | Difficult to enroll subjects - | |||
| NCT04272645 Details | 2020-07-15 Interventional | 2 | 0 | Atezolizumab Prostatic Neopl… Prostate Cancer | Coordinating site change - | |||
| NCT03745222 2018-001132-22 Details | 2020-07-15 Interventional | 3 | 1 | Tislelizumab Carcinoma, Non-… Lung Neoplasms | BeiGene and Celgene Corporation terminated the parties' global collaboration for the compound,
pending the acquisition of Celgene by Bristol Myers Squibb - | |||
| NCT03518320 Details | 2020-07-14 Interventional | 1 | 13 | Gemcitabine Nivolumab Urinary Bladder… Bladder Cancer … Bladder Cancer … Bladder Cancer … Bladder Cancer … Bladder Cancer … Bladder Cancer … Bladder Cancer … Bladder Cancer … Bladder Cancer … | Business objectives have changed - | |||
| NCT02718417 2015-003239-36 Details | 2020-07-14 Interventional | 3 | 998 | Antibodies, Mon… Avelumab Carboplatin Paclitaxel Carcinoma, Ovar… Ovarian Neoplas… Ovarian Cancer | The study was terminated based on the results of a planned interim analysis that showed
futility of efficacy. - | |||
| NCT02715804 2015-004068-13 Details | 2020-07-14 Interventional | 3 | 492 | Gemcitabine Paclitaxel Adenocarcinoma Carcinoma, Duct… Carcinoma, Panc… Pancreatic Duct… | Sponsor decision Due to the negative study outcome, development of PEGPH20 was terminated. | |||
| NCT02624700 Details | 2020-07-14 Interventional | 2 | 13 | Pemetrexed Sorafenib Breast Neoplasm… Recurrence Triple Negative… Breast Cancer Metastatic Brea… Recurrent Breas… | - Incomplete objectives due to early termination of trial. Amendment to allow more heavily pretreated subjects to be enrolled required a change in starting doses (Arm B) for all subsequently enrolled subjects. | |||
| NCT03231228 Details | 2020-07-13 Interventional | 4 | 61 | Cefazolin Postoperative I… | Stopped with agreement from FDA. - | |||
| NCT03003390 Details | 2020-07-13 Interventional | 2 | 51 | Enoxaparin Thrombosis Venous Thrombos… Deep Venous Thr… | Met protocol defined stopping rule for futility - | |||
| NCT02903407 Details | 2020-07-13 Interventional | 4 | 7 | Dexmedetomidine Midazolam Propofol Critical Illnes… Delirium Deep Sedation Ventilators, Me… | All enrolled participants completed the study protocol but the study was terminated prior to
the goal number of participants due to low recruitment Our trial was terminated prior to goal enrollment due to difficulty with enrollment in this critically ill population of patients. The data here represent a small sample size of patients and should be viewed as pilot data for hypothesis generation. | |||
| NCT02547220 2015-000726-11 Details | 2020-07-13 Interventional | 3 | 39 | Complement C1 I… Acute Antibody-… | Following a pre-scheduled interim analysis performed by the DMC, it was determined that the
study met the pre-specified criteria for futility. This study was prematurely terminated at Month 36 due to futility issue. |